1. Home
  2. OBIO vs EARN Comparison

OBIO vs EARN Comparison

Compare OBIO & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • EARN
  • Stock Information
  • Founded
  • OBIO 2017
  • EARN 2012
  • Country
  • OBIO United States
  • EARN United States
  • Employees
  • OBIO N/A
  • EARN N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • EARN Real Estate Investment Trusts
  • Sector
  • OBIO Health Care
  • EARN Real Estate
  • Exchange
  • OBIO Nasdaq
  • EARN Nasdaq
  • Market Cap
  • OBIO 200.1M
  • EARN 164.4M
  • IPO Year
  • OBIO N/A
  • EARN 2013
  • Fundamental
  • Price
  • OBIO $5.84
  • EARN $6.46
  • Analyst Decision
  • OBIO Strong Buy
  • EARN Hold
  • Analyst Count
  • OBIO 4
  • EARN 2
  • Target Price
  • OBIO $15.75
  • EARN $6.00
  • AVG Volume (30 Days)
  • OBIO 57.1K
  • EARN 485.8K
  • Earning Date
  • OBIO 11-12-2024
  • EARN 11-12-2024
  • Dividend Yield
  • OBIO N/A
  • EARN 14.86%
  • EPS Growth
  • OBIO N/A
  • EARN 275.17
  • EPS
  • OBIO N/A
  • EARN 1.02
  • Revenue
  • OBIO $2,647,000.00
  • EARN N/A
  • Revenue This Year
  • OBIO $7.68
  • EARN N/A
  • Revenue Next Year
  • OBIO $110.40
  • EARN $51.17
  • P/E Ratio
  • OBIO N/A
  • EARN $6.36
  • Revenue Growth
  • OBIO N/A
  • EARN N/A
  • 52 Week Low
  • OBIO $4.22
  • EARN $5.54
  • 52 Week High
  • OBIO $11.69
  • EARN $7.26
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 51.19
  • EARN 42.16
  • Support Level
  • OBIO $5.56
  • EARN $6.26
  • Resistance Level
  • OBIO $6.50
  • EARN $6.68
  • Average True Range (ATR)
  • OBIO 0.53
  • EARN 0.17
  • MACD
  • OBIO 0.00
  • EARN -0.01
  • Stochastic Oscillator
  • OBIO 56.58
  • EARN 35.59

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: